Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heparin seizure

This article was originally published in The Gray Sheet

Executive Summary

FDA seizes 11 lots of tainted heparin Nov. 6, including some of the type used in medical devices, from Cincinnati-based Celsus Laboratories. The over-sulfated chondroitin contaminant identified in the seized product has previously been fingered as the cause of deaths and adverse events in supplies of the blood-thinning agent imported from China (1"The Gray Sheet" June 9, 2008, In Brief). Six of the seized lots were heparin lithium, used in vacutainer blood collection tubes, some in vitro diagnostics and as a coating for capillary tubes. The other five were pharmaceutical grade
Advertisement

Related Content

Deaths linked to heparin-containing devices
Advertisement
UsernamePublicRestriction

Register

MT026770

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel